Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Movianto collaborates with identif to solve pharmaceutical counterfeit challenges

Movianto : 11 July, 2008  (Company News)
Movianto in collaboration with identif have developed a solution to counterfeit products by adopting the DNA coding method to ensure pharmaceutical products are secure.
The healthcare logistics provider Movianto, in collaboration with identif, is working to eliminate drug counterfeiting. Manufacturers have the possibility to mark their valuable products with an anti counterfeit label. 'If you want to protect your brand from misuse and guard it against loss of image, reliably and effectively, you must always remain one step ahead of the criminals', stated Marcus Weichert, managing director of identif. 'For this reason, we have specialised in safety markings that are regarded as providing an extremely high level of protection against counterfeiting - DNA markings.'

The innovative procedure makes it possible to track the distribution path of the drug from the manufacturer to the patient. To achieve this, two single strands of synthetically produced DNA are used. Due to their unique sequence of DNA building blocks, these strands fit together as a key fits in a lock. One of the single DNA strands (lock) is integrated into a safety label. The second complementary DNA strand (key) is located in a detection pen, provided separately. When the two individual DNA strands come together, an extremely specific hybridisation takes place, means that the 2 single strands are united to a complete DNA strand. If the product is genuine, the scanner will emit a positive signal.

'By using DNA coding, pharmaceutical manufacturers will be able to do more than simply guarantee to their customers that the products are genuine', explains Conor Roche, managing director, Movianto Group. 'This process will also enable manufacturers to depict the paths of the drugs in a transparent manner and to trace these.'

Movianto's pan-European network expanded fast during the last years. The company's wholly owned subsidiaries are offering their logistics and distribution services throughout Europe: in Austria, Czech Republic, Denmark, France, Germany, Ireland, Norway, Slovenia, Spain and United Kingdom.

In March 2006 a new group-wide brand name was introduced: Movianto.

Offering warehousing, transportation, cold chain logistics, administrative services as well as customer-specific services such as re-packaging and re-labelling, Movianto is committed to being the preferred European provider of logistics services to the healthcare industry.

As part of the Celesio, a Euros 22 billion revenue healthcare distribution group and market leader in Europe with wholesale branches and pharmacy chains in 16 European countries, Movianto offers an platform right across the continent.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo